IBM Clinical Development

IBM Clinical Development (recently acquired and rebranded under Merative, but historically known for its massive IBM pedigree) is a formidable, highly capable enterprise EDC and clinical data management platform. It leverages massive cloud architecture to handle incredibly complex, global trials across a vast array of therapeutic areas. It is deeply favored by massive global CROs and large pharmaceutical companies that require a highly scalable, fully unified platform capable of ingesting data not just from clinical sites, but from massive external datasets. The platform is designed as a fully unified, single-database ecosystem. When a sponsor purchases the platform, they do not just get an EDC; they have access to native, deeply integrated modules for Randomization and Trial Supply Management (RTSM), eCOA/ePRO, medical coding, and complex clinical inventory management. Because these modules share a single database, if a patient is randomized into a specific treatment arm in the RTSM, their EDC forms automatically and instantaneously update to reflect the specific clinical assessments required for that arm, eliminating integration failures. Furthermore, given its historical integration with IBM Watson, the platform features highly advanced, AI-driven medical coding. Instead of a human manually reading thousands of adverse event descriptions and attempting to map them to the MedDRA dictionary, the AI engine can automatically code massive volumes of clinical terms with high accuracy, surfacing only the complex anomalies for human review. For organizations requiring massive global scalability, deep unification, and advanced analytical capabilities, Merative's platform is an elite enterprise solution.